Breakthrough cancer treatment brings hope and challenges

October 2, 2017, The Hastings Center
cancer
Killer T cells surround a cancer cell. Credit: NIH

The first gene therapy for cancer, approved by the Food Drug Administration in August, will transform the treatment of a particular kind of cancer in children and young adults. It's transformative because it uses a patient's own immune cells to attack the cancer cells. The hope is that this is just the first of many other drugs capable of harnessing a patient's immune system.

However, this , called Kymriah (tisagenlecleucel), and similar ones in the pipeline raise difficult challenges for policy-makers. "Safety, access and cost-we have to figure all that out if everyone is going to benefit," says Karen Maschke, the first author.

Maschke, Michael Gusmano, and Hastings Center president Mildred Solomon describe the breakthrough, evaluate the challenges, and make recommendations in the October issue of Health Affairs.

The new therapy was developed by Novartis to treat children and with relapsed or refractory B-cell precursor (ALL). Called chimeric antigen receptor (CAR) T cell , it works by genetically reengineering a patient's T , in the immune system. The altered T cells are then infused into the patient to attack the .

Safety

Clinical trials by Novartis found that 52 out of 63 patients were in remission three months after receiving a one-time infusion. However, the therapy also has life-threatening neurological and other side effects experienced by 76 percent of patients, and it increases the risk of patients developing secondary cancers.

The authors point out that as CAR T cell cancer treatments continue to be tested in before obtaining FDA approval, "the FDA and Institutional Review Boards (IRBs) with oversight over human subjects research must carefully scrutinize [the risk benefit profile] to determine whether the potential benefits of the investigational treatment justifies permitting cancer patients to enroll in a study."

They also recommend that IRBs make sure that all consent forms clearly state the possibility of adverse effects and that the FDA conduct post-licensing monitoring of adverse events that patients experience. The agency is requiring Novartis to conduct a postmarketing study of the safety and efficacy of Kymriah. "However, it is an open question whether the FDA, under the administration of President Donald Trump, will withdraw licensing approval from breakthrough therapy products whose clinical use over time indicates that they are ineffective or harmful to patients," they write.

Access

The authors raise concerns that many patients who could benefit from the therapy will not have access to it-at least not for a while. That is because the highly specialized skill needed to genetically reengineer the patients' T cells, administer the infusion, and treat the serious side effects are in short supply. Kymriah will be available at certified treatment centers in only 16 states, all but four with just one treatment site. "Having fewer sites with highly trained clinical staff treating very sick is often optimal for ensuring high-quality delivery of complex treatments, but at least at first there will be a serious access challenge," they write.

Cost

"Even if the problem of limited availability can be solved, the cost of treatment still raises important questions of justice," the article explains. Kymriah will cost $475,000 for a one-time infusion, and FDA approval of a therapy does not guarantee that insurers will cover it.

"If CAR T cell therapies prove as safe and effective as other recent breakthrough treatments, the benefits will be tremendous, and demand will be high," the authors write. "However as has been the case with other recent beneficial but high-price drugs, CAR T cell therapies may lead to higher health care costs, highly limited access, and even greater inequalities in access and health outcomes. For the public to benefit from breakthrough treatments without breaking Americans' health care system or pocketbooks, ethics and wise policy making need to catch up to the science."

Explore further: FDA approves personalized cellular therapy for advanced leukemia

More information: Health Affairs (2017). DOI: 10.1377/hlthaff/2017.1032 , http://content.healthaffairs.org/content/36/10/1698.abstract

Related Stories

FDA approves personalized cellular therapy for advanced leukemia

August 30, 2017
In a landmark decision for the field of cancer immunotherapy, the U.S. Food and Drug Administration (FDA) today approved a personalized cellular therapy developed by the University of Pennsylvania and Children's Hospital ...

US clears breakthrough gene therapy for childhood leukemia

August 31, 2017
Opening a new era in cancer care, U.S. health officials have approved a breakthrough treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia.

What makes cancer gene therapy so groundbreaking?

July 19, 2017
On July 12, a Food and Drug Administration panel unanimously recommended approval for the first-ever gene therapy treatment for cancer. The treatment, known as CTL019, is a T-cell therapy developed by the pharmaceutical company ...

'Breakthrough' leukemia drug also portends 'quantum leap' in cost

August 24, 2017
When doctors talk about a new leukemia drug from Novartis, they ooze enthusiasm, using words like "breakthrough," "revolutionary" and "a watershed moment."

Patient's immune status associated with outcome following third-generation CAR T-cell therapy

September 6, 2017
Treatment with third-generation CAR T–cell therapy led to a complete response in six of 15 patients with a CD19-positive B-cell malignancy and overall survival was associated with the patient's immune status, according ...

Novel leukemia treatment could be first US gene therapy (Update)

July 12, 2017
A treatment for a common childhood blood cancer could become the first gene therapy available in the U.S.

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.